How this company measures up on the fundamentals that matter
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-20 | MATHEIS DENNIS | Director | 245,000 | $245,270 | |
| 2026-02-20 | SOKOLOV JACQUE J | Director | 123,000 | — | |
| 2026-02-20 | MCGRATH DENNIS M | Chief Financial Officer | 470,000 | — | |
| 2026-02-20 | LAPIDUS STANLEY N | Director | 123,000 | — | |
| 2026-02-20 | PALUMBO JOHN R | Director | 123,000 | — | |
| 2026-02-20 | AKLOG LISHAN | Chief Executive Officer | 2,170,000 | — | |
| 2026-02-20 | COX JAMES L | Director | 123,000 | — | |
| 2026-02-20 | MATHEIS DENNIS | Director | 123,000 | — | |
| 2026-02-20 | WHITE DEBRA JAYNE | Director | 123,000 | — | |
| 2026-02-20 | O'NEIL SHAUN | President | 620,000 | — |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15